A new approach to neurodegeneration
We focus on research and development of innovative technologies and breakthrough therapies for unmet medical needs and orphan diseases.
our model
we research
We find molecules with solid scientific data as new therapeutic opportunities.
we develop
Through a development plan we add value to molecules to become new neuroprotective drugs.
we maximize
After significant scientific evidence we maximize the efficiency of the orphan drugs for niche indications.
we optimize
To provide a rapid return on investment we optimize and complete the drug development.
a new biotech for neurological disorders
The development of the lead products CRES101 ans CRES102 for the treatments of neurodegenerative diseases strengthens the offert of innovative therapeutic solutions.
About us
We are an agile corporate structure of Directors and Scientific Advisors.
Our commitment is to turn our efforts into research, with passion, competence and boldness.
Dr. anders fugelli
Co-founder and Chairman
Dr. francois curtin
Co-founder and Vice Chairman
Prof. alois b. lang
Co-founder and Member
